Cellectar Biosciences

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Cellectar Biosciences sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 5 completed early-phase tilt top decile by trial count

Cellectar Biosciences: 10 sponsored US clinical trials, 1 recruiting.

Cellectar Biosciences sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pediatric Lymphoma, with 1 trials.

Top-decile sponsor footprint

Cellectar Biosciences ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 1

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

NCT07311993
ACTIVE NOT RECRUITING Phase 1

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

NCT05610891
ACTIVE NOT RECRUITING Phase 1

Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas

NCT03478462
ACTIVE NOT RECRUITING Phase 2

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508
COMPLETED Phase 1

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

NCT02278315
TERMINATED Phase 2

Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma

NCT01898273
COMPLETED Phase 1

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

NCT01495663
COMPLETED Phase 2

A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

NCT01058512
COMPLETED Phase 3

Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer

NCT00347412
COMPLETED Phase 2

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

NCT00345540

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 4
Phase 3 1

Therapeutic Areas

Pediatric Lymphoma 1
DIPG 1
Pediatric Brain Tumor 1
Waldenstrom Macroglobulinemia 1
Pediatric Solid Tumor 1
Small Lymphocytic Lymphoma 1
Lymphoplasmacytic Lymphoma 1
Marginal Zone Lymphoma 1
Rhabdomyosarcoma 1
Osteosarcoma 1

What is open in the Cellectar Biosciences pipeline

1 recruiting of 10 indexed (10% open); 5 completed (50%).

Phase mix: 1 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Pediatric Lymphoma (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Cellectar Biosciences: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Cellectar Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Cellectar BiosciencesAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Cellectar Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cellectar Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cellectar Biosciences page

10 registered trials is a research-attention snapshot, not an endorsement of Cellectar Biosciences or any single study.

  • 1 of Cellectar Biosciences's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pediatric Lymphoma is the condition Cellectar Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pediatric Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Cellectar Biosciences pipeline card: 10 registered trials from official public datasets.Report a data error.